FRAMES trial expected to initiate patient recruitment in upcoming weeks in Spain, Belgium and other European countries.
Two Key Opinion Leaders join Minoryx’s scientific advisory board.
In 2018 Minoryx closed a Series B funding round of €21.3M to expand the development of MIN-102 into new indications.

| Read more |

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |

NuMat Medtech, a medical technology company based at the Balearic Technological Innovation Park (ParcBIT) and involved in developing coatings for medical implants, today announces a €530,000 round of capital finance. NuMat will use the funds secured to make preclinical studies of its coatings on various types of implant and to strengthen its strategic alliances with important international players in the dental and orthopaedics industry.

| Read more |

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.

| Read more |